SCHEMBL18038956

SCHEMBL18038956

O=C(Cn1cc(S(=O)(=O)N2CCCC2)ccc1=O)c1ccc(-c2cccc(F)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ GRIN2B Q13224 2/20 0.45
▸ GAA P10253 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ TP53 P04637 1/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038965 0.91 L3MBTL1 (0.52) ALDH1A1L3MBTL1GAAMAPTKDM4E
SCHEMBL18039017 0.90 POLB (0.51) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038954 0.89 L3MBTL1 (0.56) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038959 0.89 L3MBTL1 (0.56) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038989 0.89 L3MBTL1 (0.56) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038957 0.88 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038953 0.88 L3MBTL1 (0.53) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL30207105 0.88 GAA (0.47) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038967 0.88 GAA (0.47) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL18038951 0.87 L3MBTL1 (0.52) ALDH1A1L3MBTL1GRIN2BGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 ALDH1A1 52/4885KMT2A 3033/4885MEN1 494/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 ALDH1A1 49/4885KMT2A 3024/4885MEN1 490/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 ALDH1A1 52/4885KMT2A 3033/4885MEN1 494/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 ALDH1A1 49/4885KMT2A 3024/4885MEN1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback